Rekvina Laboratories Faces Open Offer Amid Financial Weakness

Three acquirers – Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel – are initiating an open offer to acquire up to 28,90,100 equity shares of Rekvina Laboratories Ltd. The bid represents 26% of the company's expanded capital and is priced at ₹10 per share, with the offer period set from May 14 to May 27, 2026. The maximum total consideration for the offer is ₹2.89 Crore.

This move is linked to Rekvina Laboratories' recent decision to acquire Radiant Parenterals Limited for ₹4.63 Crore through a share swap.

Potential Control Change and Shareholder Exit

The open offer signals a potential change in control for Rekvina Laboratories. The acquirers aim to gain significant stake and control, with possible plans to continue the current business or diversify later, pending approvals. For existing shareholders, the offer presents an exit opportunity at a price higher than recent market trading levels, though the company's weak financial standing is a key concern.

Company Operations and Financial Struggles

Rekvina Laboratories, founded in 1988 and based in Vadodara, is a pharmaceutical company manufacturing and marketing formulations, alongside offering contract research and manufacturing services. However, its financial performance has been consistently poor. The company reported losses in recent fiscal years and the first nine months of FY26, with very low revenue.

Furthermore, Rekvina Laboratories' shares previously faced a trading suspension due to non-compliance with listing regulations. A low interest coverage ratio also points to significant financial strain. The current open offer is part of a larger corporate restructuring that includes the acquisition of Radiant Parenterals Limited.

Post-Offer Outlook and Shareholder Actions

If the open offer succeeds, a significant shift in Rekvina Laboratories' ownership and control structure is expected. New management might introduce strategic changes, possibly diversifying the company's business activities. Public shareholders have a specific window to sell their shares at ₹10 each, offering a potential opportunity to exit their investment.

Key points to watch include the successful closure of the offer by its May 27, 2026 deadline, the settlement process, and timely payment to tendering shareholders. The market price of Rekvina shares will likely be watched closely against the offer price, especially considering past price volatility. The company's compliance with minimum public shareholding rules and SEBI regulations post-acquisition will also be crucial.

Industry Context

Rekvina Laboratories operates in the small-cap pharmaceutical sector in India. While large companies like Sun Pharma and Cipla dominate the industry, direct peers for an open offer of this size are limited. The small-cap pharma market typically features companies focused on formulations and APIs, facing significant competition and regulatory scrutiny.

Financial Snapshot

Here are key financial figures for Rekvina Laboratories:

• Nine months ended Dec 31, 2025: Revenue ₹54.18 lakh, Net loss ₹19.42 lakh (Standalone).
• Fiscal Year ended Mar 31, 2025: Net loss ₹13.71 lakh (Standalone).